Datopotamab deruxtecan is an ADC targeting trophoblast cell surface antigen 2 (TROP2), a transmembrane glycoprotein widely expressed in epithelial cancers, including breast cancer.129 The antibody is conjugated to a topoisomerase I inhibitor payload, which, after internalization, induces DNA damage leading to apoptosis. Here, TACSTD2 is linked to breast cancer.